Skip to content
DataLookout
Menu

NCT06276088

Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy

StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Mar 2024); last known: Recruiting
  2. Minor Site contacts updated at 1 of 5 sitesv3
  3. Minor Study title shortened, about 5 wordsv2
  4. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Incidence of hyperprogression
Timeframe: 2 years

Secondary (3)

Event-free survival
Progression-free survival
Overall survival

Sites

5 sites in 1 country